EVOQ therapeutics Archives - Inside Precision Medicine

Inside Precision Medicine Gilead And EVOQ Ink Deal Worth up to $685M For Autoimmune Diseases

Dentritic Cell activate T cells, trigger immune responses, they are responsible of cells protection of the body.

News & Features

Gilead And EVOQ Ink Deal Worth up to $685M For Autoimmune Diseases

January 4, 2023

Related Content

GSK Inks Two Deals with Relation for Fibrotic Diseases and Osteoarthritis

GSK Inks Two Deals with Relation for Fibrotic Diseases and Osteoarthritis

Beam Therapeutics Sickle Cell Base Editing Works, Not Cause of Patient Death

Beam Therapeutics Sickle Cell Base Editing Works, Not Cause of Patient Death

GSK Inks Multi-Year Deal Around Muna’s Spatial Multi-Omics Platform

GSK Inks Multi-Year Deal Around Muna’s Spatial Multi-Omics Platform

New Trispecific Antibody Immunotherapy Shows Promise for Treating Glioblastoma

New Trispecific Antibody Immunotherapy Shows Promise for Treating Glioblastoma